Nat Med 2013,
PMID: 23502960
Gebeshuber, Christoph A; Kornauth, Christoph; Dong, Lihua; Sierig, Ralph; Seibler, Jost; Reiss, Martina; Tauber, Stefanie; Bilban, Martin; Wang, Shijun; Kain, Renate; Böhmig, Georg A; Moeller, Marcus J; Gröne, Hermann-Josef; Englert, Christoph; Martinez, Javier; Kerjaschki, Dontscho
Focal segmental glomerulosclerosis (FSGS) is a frequent and severe glomerular disease characterized by destabilization of podocyte foot processes. We report that transgenic expression of the microRNA miR-193a in mice rapidly induces FSGS with extensive podocyte foot process effacement. Mechanistically, miR-193a inhibits the expression of the Wilms' tumor protein (WT1), a transcription factor and master regulator of podocyte differentiation and homeostasis. Decreased expression levels of WT1 lead to downregulation of its target genes PODXL (podocalyxin) and NPHS1 (nephrin), as well as several other genes crucial for the architecture of podocytes, initiating a catastrophic collapse of the entire podocyte-stabilizing system. We found upregulation of miR-193a in isolated glomeruli from individuals with FSGS compared to normal kidneys or individuals with other glomerular diseases. Thus, upregulation of miR-193a provides a new pathogenic mechanism for FSGS and is a potential therapeutic target.
Diseases/Pathways annotated by Medline MESH: Glomerulosclerosis, Focal Segmental
Document information provided by NCBI PubMed
Text Mining Data
transcription factor ⊣ miR-193a: "
Mechanistically,
miR-193a inhibits the expression of the Wilms' tumor protein ( WT1 ), a
transcription factor and master regulator of podocyte differentiation and homeostasis
"
Wilms' tumor protein ⊣ miR-193a: "
Mechanistically, miR-193a inhibits the expression of the Wilms' tumor protein ( WT1 ), a transcription factor and master regulator of podocyte differentiation and homeostasis
"
Manually curated Databases
No curated data.